FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2260447624> ?p ?o ?g. }

• W2260447624 abstract "Background: Pharmaceutical companies play an important role in new drug development and approval in an environment where performing RCTs has become increasingly costly and complex. However, myriad questions about the impact of clinical, surgical and radiotherapy interventions equally require adequate hypothesis testing in RCTs. A potential lack of funding for RCTs not directly related to new drug development might lead to important gaps in clinical knowledge. Methods: We searched PubMed for all RCTs published between 01/2009 and 12/2013 in breast cancer. All articles published in this period were manually screened for eligibility. We included only RCTs with clinical endpoints such as TTP, PFS, OS and response rate. Two investigators independently selected phase 2 and phase 3 RCTs with at least 50 patients published in English. We also searched National Cancer Institute (NCI) data for all active, therapeutic phase 3 trials that are currently enrolling patients (as of 05/05/2014). We classified eligible trials according to the type of intervention (drugs, radiotherapy or surgery) and the stated funding source (industry versus nonprofit). Results: We retrieved 1,676 PubMed studies of which 247 (15%) were eligible. 218 (88%) of the RCTs evaluated drugs, 14 (6%) radiotherapy and 15 (6%) surgery. 183/247 (74%) RCTs were funded entirely or partially by industry (pharmaceutical and device companies) and 64/247 (26%) by nonprofit organizations (government, academic centers or foundations). There was a significant association between source of funding and type of intervention: 183/218 RCTs (83%) evaluating drugs were funded by industry, in comparison to none of surgical and radiotherapy RCTs (P Conclusions: The vast majority of RCTs in oncology relates to drug development and is being funded by industry, while 100% of RCTs evaluating surgical or radiotherapy related questions are not industry funded. This scenario seems not be changing over the last years given that the comparison between published trials and active trials shows the same scenario. Even though new drug development is of paramount importance, the extent to which clinically relevant issues are not being properly addressed by RCTs, at least in part due to lack of funding, should be considered and further evaluated. The oncologic community, as well as academic and nonprofit organizations, including governments, need to work together to forge new and alternative forms of research funding in order to allow us to answer critical clinical questions that we, as oncologists, face in our daily practice. Citation Format: Artur Katz, Fernando Santini, Fabio Y Moraes, Andrea K Shimada, Caroline Chaul, Manuel C Abraao, Everardo D Saad. Relationship between type of therapeutic intervention and funding source in randomized clinical trials (RCTs) in breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P4-18-02." @default.
• W2260447624 created "2016-06-24" @default.
• W2260447624 creator A5004647107 @default.
• W2260447624 creator A5016682199 @default.
• W2260447624 creator A5017636503 @default.
• W2260447624 creator A5029627466 @default.
• W2260447624 creator A5030091305 @default.
• W2260447624 creator A5065360052 @default.
• W2260447624 creator A5076977196 @default.
• W2260447624 date "2015-04-30" @default.
• W2260447624 modified "2023-09-27" @default.
• W2260447624 title "Abstract P4-18-02: Relationship between type of therapeutic intervention and funding source in randomized clinical trials (RCTs) in breast cancer" @default.
• W2260447624 doi "https://doi.org/10.1158/1538-7445.sabcs14-p4-18-02" @default.
• W2260447624 hasPublicationYear "2015" @default.
• W2260447624 type Work @default.
• W2260447624 sameAs 2260447624 @default.
• W2260447624 citedByCount "0" @default.
• W2260447624 crossrefType "proceedings-article" @default.
• W2260447624 hasAuthorship W2260447624A5004647107 @default.
• W2260447624 hasAuthorship W2260447624A5016682199 @default.
• W2260447624 hasAuthorship W2260447624A5017636503 @default.
• W2260447624 hasAuthorship W2260447624A5029627466 @default.
• W2260447624 hasAuthorship W2260447624A5030091305 @default.
• W2260447624 hasAuthorship W2260447624A5065360052 @default.
• W2260447624 hasAuthorship W2260447624A5076977196 @default.
• W2260447624 hasConcept C121608353 @default.
• W2260447624 hasConcept C126322002 @default.
• W2260447624 hasConcept C142724271 @default.
• W2260447624 hasConcept C159110408 @default.
• W2260447624 hasConcept C168563851 @default.
• W2260447624 hasConcept C204787440 @default.
• W2260447624 hasConcept C27415008 @default.
• W2260447624 hasConcept C2780665704 @default.
• W2260447624 hasConcept C509974204 @default.
• W2260447624 hasConcept C512399662 @default.
• W2260447624 hasConcept C530470458 @default.
• W2260447624 hasConcept C535046627 @default.
• W2260447624 hasConcept C71924100 @default.
• W2260447624 hasConceptScore W2260447624C121608353 @default.
• W2260447624 hasConceptScore W2260447624C126322002 @default.
• W2260447624 hasConceptScore W2260447624C142724271 @default.
• W2260447624 hasConceptScore W2260447624C159110408 @default.
• W2260447624 hasConceptScore W2260447624C168563851 @default.
• W2260447624 hasConceptScore W2260447624C204787440 @default.
• W2260447624 hasConceptScore W2260447624C27415008 @default.
• W2260447624 hasConceptScore W2260447624C2780665704 @default.
• W2260447624 hasConceptScore W2260447624C509974204 @default.
• W2260447624 hasConceptScore W2260447624C512399662 @default.
• W2260447624 hasConceptScore W2260447624C530470458 @default.
• W2260447624 hasConceptScore W2260447624C535046627 @default.
• W2260447624 hasConceptScore W2260447624C71924100 @default.
• W2260447624 hasLocation W22604476241 @default.
• W2260447624 hasOpenAccess W2260447624 @default.
• W2260447624 hasPrimaryLocation W22604476241 @default.
• W2260447624 hasRelatedWork W1969634300 @default.
• W2260447624 hasRelatedWork W2062145209 @default.
• W2260447624 hasRelatedWork W2072019641 @default.
• W2260447624 hasRelatedWork W2098846386 @default.
• W2260447624 hasRelatedWork W2126650051 @default.
• W2260447624 hasRelatedWork W2133469067 @default.
• W2260447624 hasRelatedWork W2152020848 @default.
• W2260447624 hasRelatedWork W2317940379 @default.
• W2260447624 hasRelatedWork W2416084933 @default.
• W2260447624 hasRelatedWork W2418978739 @default.
• W2260447624 hasRelatedWork W2425477507 @default.
• W2260447624 hasRelatedWork W2507119797 @default.
• W2260447624 hasRelatedWork W2563003498 @default.
• W2260447624 hasRelatedWork W2889229514 @default.
• W2260447624 hasRelatedWork W2908120283 @default.
• W2260447624 hasRelatedWork W2985351046 @default.
• W2260447624 hasRelatedWork W3099963685 @default.
• W2260447624 hasRelatedWork W3156774850 @default.
• W2260447624 hasRelatedWork W3193792805 @default.
• W2260447624 hasRelatedWork W3197635523 @default.
• W2260447624 isParatext "false" @default.
• W2260447624 isRetracted "false" @default.
• W2260447624 magId "2260447624" @default.
• W2260447624 workType "article" @default.